Lamlique (lamotrigine hemifumarate)

Where it stands

Lamlique (lamotrigine hemifumarate) was approved by the US FDA on 2026-09-25 under NDA221109. The sponsor is Azurity. The records list this approval as the only milestone, and it is an official source.

The product is an oral suspension and the records classify it as a new active ingredient. The records do not state the indication or therapeutic area, so this analysis cannot say which patients or conditions the product is approved for. The same applies to dosing, age groups and any restrictions on use. These details are in the approved prescribing information, which is not part of the records.

Regulatory pathway and designations

The product was approved in the US through a New Drug Application (NDA221109). The only designation recorded is "New active ingredient". The records do not show any expedited-development designations, such as priority review, orphan status or breakthrough therapy. They also give no review timeline, PDUFA goal date, advisory committee activity or post-marketing requirements. None of these should be assumed.

The CHMP opinion date is blank because this is a US-only record. The records show no EU filing or EMA procedure for Lamlique, so nothing can be said about European status.

The records do not explain how the new active ingredient classification relates to the lamotrigine hemifumarate salt form. Anyone relying on that classification, for example for exclusivity assumptions, should check the FDA approval documentation directly. The records alone do not support any conclusion about exclusivity.

Safety and pharmacovigilance

The records contain no safety data. They include no label warnings, boxed warning information, adverse event data, REMS requirements or post-marketing commitments.

Safety teams should read the final FDA-approved labeling for contraindications, warnings and monitoring requirements. They should also check whether any post-marketing studies or risk management measures were required. Until the label is reviewed, no safety profile can be attributed to this product from the records.

What to watch

The records do not cover forward-looking events. The first step is to obtain the approval letter and prescribing information to confirm the indication, population, dosing and any safety conditions.

Beyond that, professionals may want to track commercial launch timing, label updates, any post-marketing requirements issued with the approval, and whether the sponsor files in other regions. None of these is in the records, so the status and timing of each remain unknown.